We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

60 hedge funds and large institutions have $773M invested in Design Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

480% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 5

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

86% more capital invested

Capital invested by funds: $415M → $773M (+$358M)

15% more funds holding

Funds holding: 52 → 60 (+8)

14.14% more ownership

Funds ownership: 50.85% → 64.98% (+14%)

Holders
60
Holders Change
+8
Holders Change %
+15.38%
% of All Funds
0.92%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
13
Increased
29
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.4M
3
Principal Financial Group
Principal Financial Group
Iowa
+$5.18M
4
EC
EcoR1 Capital
California
+$4.98M
5
ACA
Avoro Capital Advisors
New York
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.4M
2
CS
Credit Suisse
Switzerland
-$3.47M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.72M
4
Citadel Advisors
Citadel Advisors
Florida
-$650K
5
OCA
Octagon Capital Advisors
New York
-$219K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$126K +$74K +4,311 +271%
SG Americas Securities
52
SG Americas Securities
New York
$121K +$96.8K +5,639 New
Legal & General Group
53
Legal & General Group
United Kingdom
$53K +$20.4K +1,187 +93%
AIP
54
Ameritas Investment Partners
Nebraska
$44K +$17.1K +998 +94%
TRCT
55
Tower Research Capital (TRC)
New York
$27K +$14.2K +825 +185%
Osaic Holdings
56
Osaic Holdings
Arizona
$5K +$1.87K +109 +114%
Daiwa Securities Group
57
Daiwa Securities Group
Japan
$3K +$2.78K +162 New
SOW
58
State of Wyoming
Wyoming
$2K -$69 -4 -5%
UBS Group
59
UBS Group
Switzerland
$1K -$18.9K -1,099 -97%
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$280 +$225K +13,126 New
CS
61
Credit Suisse
Switzerland
– -$3.47M -235,938 Closed
OCA
62
Octagon Capital Advisors
New York
– -$219K -14,926 Closed
Millennium Management
63
Millennium Management
New York
– -$208K -14,169 Closed
PSC
64
Piper Sandler & Co
Minnesota
– -$37K -2,500 Closed
SO
65
STRS Ohio
Ohio
– -$29K -2,000 Closed
1 2
3

DSGN Hedge Fund Activity: Q4 2021 in Review

60 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2021, worth a combined $773M — up 86% from $415M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new DSGN positions and 5 closed out — a net gain of 8 holders — while 29 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $11.4M.

  • 60 institutional investors held Design Therapeutics (DSGN) as of Q4 2021, up from 52 in Q3 2021.
  • Funds reported $773M of Design Therapeutics stock for Q4 2021, up 86% quarter-over-quarter.
  • 13 funds opened new Design Therapeutics positions in Q4 2021 and 5 closed out, a net change of +8 holders.
  • The largest Design Therapeutics buyer in Q4 2021 was BlackRock, an estimated $15.5M added.
  • The largest Design Therapeutics seller in Q4 2021 was T. Rowe Price Associates, an estimated $11.4M sold.

Based on aggregated 13F filings for Q4 2021.